Periodontal disease results from the interaction of the host defence mechanisms with the microbial dental plaque. Analysis of gingival crevicular Huid (GCF) provides a non-invasive means of evaluating the role of the host response in periodontal disease. Based on our previous study, demonstrating increased levels of neopterin in GCF and saliva from patients with aggressive periodontitis (AgP), the aim of this study was to evaluate the effect of periodontal treatment on the levels of neopterin in GCF, saliva and urine of patients with AgP. Pre-treatment values of neopterin in GCF were 4.04 ± 0.86 nmol/ml for the AgP group (n=8) and 2.68 ± 0.90 nmol/ml f y r the control group (n=8; difference not significant). After periodontal treatment, the level of ncoptei in was found 2.38 ± 0.72 nmol/ml in the patient group which did not differ from pre-treatment levels. The salivary neopterin concentration was higher in both AgP groups (14.14 ± 2.85 nmol/1 and 8.02 ± 3.12 nmol/1, before and after periodontal treatment) than in controls (2.58 ± 0.3 nmol/1; both p<0.05). No significant difference in salivary neopterin level was observed in patients before and after periodontal treatment.
Introduction
Periodontal diseases comprise a group of infectious diseases in which bacteria and their by-products are the principal etiologic agents (1) . The role of the host in determining the outcome of the bacterial challenge seems to be critical in periodontal diseases. The products of inflammatory responses occurring within the periodontium during the disease can be found in gingival crevicular fluid (GCF) which is an inflammatory exudate originating from serum (2) . Neopterin, a marker of cellular immune activation, is biologically stable and it can be easily quantified in human body fluids (3) . Therefore, determination of neopterin in oral fluids such as GCF, the volume of which increases with the degree of gingival inflammation, was thought to be useful for predicting the prognosis and diagnosis of aggressive periodontitis (AgP). In AgP the cellmediated immune responses play important roics in immunopathogenesis (4, 5) . AgP is a highly destructive disease and characterised by a marked collagen attachment and alveolar bone loss around teeth. The age of the early onset is prior to 35 years. In our previous study, we found that neopterin concentrations in GCF was higher in AgP compared to healthy controls, and this was the first report demonstrated the presence of neopterin in GCF (5).
The main goal of this study was to determine the effectiveness of the periodontal treatment by measure ment of neopterin concentrations in GCF, saliva and urine of patients with AgP.
Materials and Methods
Eight AgP patients (6 (5 female and 3 male; mean age, 21.5 years;  range, 21 to 22) were recruited, and informed consent explaining all procedures and objectives of the study was obtained. All subjects were systemically healthy, and also had not received any periodontal treatment or medication in the past 6 months. After periodontal examination, all the patients were subjected to basic periodontal therapy including oral hygiene instruction and plaque control evaluation, supra-and subgingival scaling and root planing. Subsequently, patients were re-evaluated as to the necessity of periodontal surgery and the patients with unresolved sites were scheduled for surgical therapy. Plaque index (PI) (6), gingival index (GI) (7), probing depth (PD) and clinical attachment leve! (CAL) were recorded to assess the response to the periodontal therapy at baseline (B) and 6 months after completing the periodontal treatment (APT).
paper strips before and immediately after the collection (Precisa 62 A, Precisa Instruments AG, Dietikan, Switzerland). The mass (mg) of the fluid on each strip was converted to volume in milliliters by assuming that the density of GCF was 1 g/ml (8) . GCF from each strip was eluted with 100 μΐ of Hank's buffer following incubation at 4°C for 2 hours. Saliva. For collecting the saliva specimens, subjects were instructed to rinse their mouth thoroughly with water and to chew a standardized paraffin wax for stimulating the production of saliva, which was collected every 60s to yield a total volume of 1.5 ml of each sample. Samples were centrifugcd for 10 min at 3000 rpm at 4°C to remove any particulate matter.
Urine. The samples were immediately enveloped in tin foil to protect them from the light and stored at -70°C until measurement.
Sample collection and preparation GCF. saliva and urine samples from the patients were collccted for detection of the neopterin levels before and 6 months after the treatment. All samples were collected in the morning, kept from direct light, and stored at -70°C until assayed.
Gingiva! crevicular fluid. GCF from the AgP group was sampled by using 2x8 mm filter paper strips from the gingival crevices of six teeth with >5 mm PD prior to periodontal treatment. GCF from the controls was collected from the crevices of 6 teeth with clinically non-inflamed gingiva. Strips contaminated by saliva or Κ \iJ were discarded. The strips were sealed in p. Ί\ prop} lene containers. To determine the amount of GCF. an electronic balance was used for weighing the
Determination
of neopterin Neopterin concentrations of all biological samples were determined by a commercially available Neopterin ELISA kit (IBL, Hamburg, Germany) The optical density was measured at 450 nm by using ELISA 96-well microplate reader (Sunrise GmbH. Tecan, Vienna, Austria).
Neopterin concentration in each GCF sample was expressed as nmol/ml by considering GCF volume of each patient and calculated from the measured neopterin concentration in nmol/L divided by GCF volume.
Urinary neopterin levels of the specimens were given as μπιοί neopterin/mol creatinine. Creatinine levels were measured spectrophotometrically by alka- Tokyo, Japan) (9).
Table 1. Clinical parameters and GCF volumes of the control group (C) and the aggressive periodontitis groups at the baseline (B) and after the periodontal treatment (APT) (Mean ± SEM).

Sta t is ti cal ana lys is
All results were expressed as mean ± standard error 
Results
Clinical variables and GCF volumes of controls and patient groups at baseline and after treatment are given in Table 1 . Statistically significant changes were observed for Gì, PD and CAL parameters of both full mouth and sampled sites after the treatment.
GCF neopterin levels at baseline appeared higher in patients (4.04 ± 0.86 nmol/ml) than in the control group (2.68 ± 0.90 nmol/ml). However, the concentration of neoptcrin in GCF was not significantly different bei ween controls and patients in both groups at baseline and after treatment (Fig .1 ) . After periodontal treatment, neopterin concentrations were 2.38 ± 0.72 nmol/ml and did not differ from pre-treatnieni levels
The GCF volume was higher in patients before treatrneni than in the controls (p<0.01 ). There was also a significant decrease in GCF volume between before and after treatment (p<0.05). However, there was not any significant difference between patients after treatment and the control groups (Table 1) .
:t> J (Fig. 2) .
No statistically significant correlation was found between the clinical parameters and neopterin conctligation in GCF and saliva in both full-mouth and the sampled sites (Table 1) .
There was not any difference in urinary neopterin levels of the patients before treatment (188.5 ± 30.98 μιηοί neopterin/mol creatinine) and controls (168.! χ 20.21 μιηοί neopterin/mol creatinine). After periodontal treatment, urinary neopterin levels were higher (310.1 ± 39.82 μιτιοί neopterin/mol creatinine) than levels of the patients before treatment and of controls (both p<0.05; Fig. 3 ). 
Discussion
Recent studies on the natural history of human periodontal disease suggest that traditional clinical measures of disease severity are not indicative of ongoing or future disease progression (10) . Determination of the presence of inflammatory products found in GCF may be of value in evaluating both periodontal disease status and the outcome of therapy. We previously found that the neopterin levels in GCF and in saliva were higher in AgP patients than in healthy controls (5). However there has been no evidence of the cffcct of the periodontal treatment on the profile of neopterin, so far. In this study, the mean neopterin concentration in GCF was higher in AgP patients compared to that in controls, although the difference between the two groups was not statistically significant. The mean neopterin level in GCF was reduced after treatment but it was not statistically significant. This might be partially due to the insufficient number of subjects.
Activated macrophages were shown to produce neopterin and this might also be valid for our patients since macrophage infiltration and activation are known to be characteristics of chronic inflammation like periodontitis, provoked by pathogenic bacteria. Also since neopterin is a macrophage activation marker we assume that the higher neopterin levels in AgP might rcflect the enhanced macrophage infiltration to the periodontal lesion. Macrophages which play a direct and important function in cell-mediated immunity, contain peroxidase, several acid hydrolases and collagenase (11) . Macrophage coliagenase may have a significant role in collagcn breakdown in the periodontal disease process. The neopterin level might be an indicator of these host mechanisms leading to tissue destruction.
Vrecko et al (i2) showed that neopterin concentration in salivary specimens from patients with periodontitis tend to raise correlating statistically significantly with the number of the teeth affected. Our results were in accordance with this finding and we also detected that salivary neopterin concentration was different in patients with AgP before and after treatment as compared to controls. The decrease in the salivary neopterin levels after the treatment seems to indicate the effectiveness of the treatment, but within the limits of the study the difference in patients at baseline and after treatment was non-significant.
There was not any difference in urinary neopterin levels between the patient and control groups, however after treatment, the urinary neopterin levels in AgP appeared to be somehow higher. Periodontal diseases stimulate the local immune response in patients and probably systemic response might not be involved in the disease process. It seems possible that the higher urinary neopterin levels despite the periodontal treatment might be due to any systemic contribution which was not related to the periodontal disease.
Therapies improved the clinical parameters of the patients with periodontal disease, and there was visible gingival tissue improvement, although we did not find any significant correlation between neopterin in GCF and saliva and clinical variables, in this study. This is consistent with the findings of that past history of periodontal disease (probing depth) and current superficial inflammation (bleeding on probing and GCF volume) does not reflect activity in the apical aspects of the periodontal lesion (13) .
Our data indicated that the cellular immune activation biomarker neopterin might be closely associated with the initiation and progression of periodontal disease and might further contribute to collagen degradation as well as being an indicator for the effectiveness of the periodontal treatment. However, more clinical investigations conducted on larger series are clearly required for further determination of the neopterin levels in oral biological fluids in periodontal diseases.
